B-Cell CD20 Expression
0092099
Ordering Recommendation
 
Mnemonic
CD20
Methodology
Flow Cytometry
Performed
Sun-Sat
Reported
1-2 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Flow Cytometry Test Request Form RecommendedFlow Cytometry Test Request Form Recommended

Specimen Required
Patient Preparation
  
Collect
Green (sodium heparin). Also acceptable: Lavender (EDTA) or pink (K2EDTA).  
Specimen Preparation
Transport 5 mL whole blood.  
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Specimen should be received within 48 hours of collection for optimal viable testing.  
Unacceptable Conditions
Frozen specimens. Specimens greater than 48 hours old. Clotted or hemolyzed specimens.  
Remarks
Provide CBC, Wright's stained smear (if available), clinical history, differential diagnosis, and any relevant pathology reports.  
Stability
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
Refer to report.

See Compliance Statement A: www.aruplab.com/CS
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
 
Note
Monoclonal antibody-based therapies such as Rituximab that target the CD20 antigen, are being used to treat patients with a variety of B-cell lymphomas and leukemias, as well as in the treatment of some autoimmune disorders. The effectiveness of these therapies for B-cell lymphomas and leukemias requires that the B-cell leukemia or lymphoma cells express CD20. This test examines whether surface CD20 antigen expression can be identified on any B-cells present in the submitted specimen. This test will also identify CD19 antigen expression and the percentage of expression.
CPT Code(s)
88184 First marker and 88185 Each additional marker; AND 88187 interpretation for 2-8 markers
Components
Component Test Code*Component Chart NameLOINC
0095234Interpretation50595-8
0096213% CD198117-4
0096214% CD208119-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • CD20 on B Cells
  • Rituximab Therapy CD20